Abstract
Background: The pathological activation of innate immune system may contribute to the development of cardiometabolic diseases. The interferon regulatory factor (IRF) family members, which are the major transcription factors in innate immune signaling, are implicated in cardiometabolic diseases.
Objective: The aim of this review is to summary the current knowledge of the biological functions of IRFs in innate immune responses and immune cell development, and highlight our contemporary understanding of the functions and molecular mechanisms of IRFs in metabolic diseases, cardiovascular remodeling, and stroke.
Results: IRFs are the essential regulators of cardiometabolic diseases via immune-dependent and - independent manners.
Conclusion: IRFs signaling is the promising target to manage the initiation and progression of cardiometabolic disorders.
Keywords: Interferon regulatory factor signaling, metabolic diseases, cardiac remodeling, vascular injury, stroke, vascular remodeling.
Graphical Abstract
Current Drug Targets
Title:Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges
Volume: 18 Issue: 15
Author(s): Yaxing Zhang, Xiao-Jing Zhang and Hongliang Li*
Affiliation:
- Department of Cardiology, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan 430060,China
Keywords: Interferon regulatory factor signaling, metabolic diseases, cardiac remodeling, vascular injury, stroke, vascular remodeling.
Abstract: Background: The pathological activation of innate immune system may contribute to the development of cardiometabolic diseases. The interferon regulatory factor (IRF) family members, which are the major transcription factors in innate immune signaling, are implicated in cardiometabolic diseases.
Objective: The aim of this review is to summary the current knowledge of the biological functions of IRFs in innate immune responses and immune cell development, and highlight our contemporary understanding of the functions and molecular mechanisms of IRFs in metabolic diseases, cardiovascular remodeling, and stroke.
Results: IRFs are the essential regulators of cardiometabolic diseases via immune-dependent and - independent manners.
Conclusion: IRFs signaling is the promising target to manage the initiation and progression of cardiometabolic disorders.
Export Options
About this article
Cite this article as:
Zhang Yaxing , Zhang Xiao-Jing and Li Hongliang *, Targeting Interferon Regulatory Factor for Cardiometabolic Diseases: Opportunities and Challenges, Current Drug Targets 2017; 18 (15) . https://dx.doi.org/10.2174/1389450116666150804110412
DOI https://dx.doi.org/10.2174/1389450116666150804110412 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Current Pharmaceutical Biotechnology A Fresh Prospect of Extracellular Matrix Hydrolytic Enzymes and Their Substrates
Current Pharmaceutical Design Indoleamine 2,3-Dioxygenase in Immune Suppression and Cancer
Current Cancer Drug Targets Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Current Drug Targets Busulfan Use in Hematopoietic Stem Cell Transplantation: Pharmacology, Dose Adjustment, Safety and Efficacy in Adults and Children
Current Drug Safety Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) An Interplay between Obesity and Inflammation in Gestational Diabetes Mellitus
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Bioinformatics and Biotechnology)
Current Biotechnology Current Applications of Therapeutic Gases in Neonatal Intensive Care
Current Pediatric Reviews In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Sam Domains in Multiple Diseases
Current Medicinal Chemistry Post-Streptococcal Reactive Arthritis
Current Rheumatology Reviews Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Editorial [Hot Topic:Avian and Pandemic Influenza Cytokine Storm, Inflammation,Tissue and Therapeutic Opportunities (Guest Editor: Jonathan P. Wong)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanotechnology can Provide Therapeutic Agent by Targeting Molecular Structures of SARS-CoV-2 (COVID-19): A Mini-Review
Letters in Drug Design & Discovery From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
CNS & Neurological Disorders - Drug Targets The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer’s Disease
Current Medicinal Chemistry Non-Viral Gene Delivery to Mesenchymal Stem Cells: Methods, Strategies and Application in Bone Tissue Engineering and Regeneration
Current Gene Therapy Noradrenaline-mediated Inhibition of Inflammatory Cytokines is Altered in Macrophages from Obese Zucker Rats: Effect of Habitual Exercise
Endocrine, Metabolic & Immune Disorders - Drug Targets New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets